CYP2C19 and epilepsy: While Valdivia reported the genotypic frequency of CYP2C19*2 (*1/*1: n = 70, 87.5%; *1/*2: n = 6, 7.5%, p = 0.42; *2/*2: n = 4, 5.0%, p = 0.21) and CYP2C19*3 (*1/*1: n = 66, 82.5%; *1/*3: n = 14, 17.5%, p = 0.51; *3/*3: n = 0, 0.0%) for patients with epilepsy and for admixed volunteers from the city of Arequipa [43].